Moderna and other vaccines stocks are down after the FDA's top vaccine official resigns [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
Moderna, known for its mRNA Covid-19 vaccine, dropped 13%, while Novavax ( NVAX ) and BioNTech ( BNTX ) both fell more than 9%. Pfizer ( PFE ) declined nearly 2%. The stock moves come as Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, submitted his resignation letter Friday. In that role, which he had held since 2016, he oversaw the approval of vaccines and other biologic drugs, including gene therapies. The Wall Street Journal first reported , citing unnamed sources, that Marks resigned after an official at the Department of Health and Human Services (HHS) told him he could either quit or be fired. HHS and the FDA did not immediately respond to a request for comment from Quartz. In his resignation letter , Marks cited fundamental disagreements with HHS Secretary Robert F. Kennedy Jr., a longtime critic of vaccines. “As you are aware, I was willing to work to address the Secretary's concerns regarding vaccine safety and transparency,” Marks wr
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Pfizer leads COVID-19 vaccine peers lower after revamped guidance [Seeking Alpha]Seeking Alpha
- New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use [Yahoo! Finance]Yahoo! Finance
- Why I Wouldn't Touch Novavax With a 10-Foot Pole [Yahoo! Finance]Yahoo! Finance
- Novavax (NASDAQ:NVAX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Novavax, Inc. (NVAX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 12/15/25 - Form 4
- 11/12/25 - Form SCHEDULE
- 11/6/25 - Form 8-K
- NVAX's page on the SEC website